Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Silence Therapeutics (SLN) Change in Receivables: 2020-2025

Historic Change in Receivables for Silence Therapeutics (SLN) over the last 4 years, with Sep 2025 value amounting to -$62,000.

  • Silence Therapeutics' Change in Receivables rose 96.46% to -$62,000 in Q3 2025 from the same period last year, while for Sep 2025 it was -$383,000, marking a year-over-year decrease of 165.65%. This contributed to the annual value of $904,000 for FY2024, which is 330.61% up from last year.
  • Per Silence Therapeutics' latest filing, its Change in Receivables stood at -$62,000 for Q3 2025, which was down 875.00% from $8,000 recorded in Q2 2025.
  • Silence Therapeutics' 5-year Change in Receivables high stood at $15.0 million for Q3 2023, and its period low was -$13.8 million during Q2 2023.
  • Its 3-year average for Change in Receivables is $46,378, with a median of -$62,000 in 2025.
  • Per our database at Business Quant, Silence Therapeutics' Change in Receivables tumbled by 3,243.59% in 2023 and then skyrocketed by 1,158.72% in 2024.
  • Silence Therapeutics' Change in Receivables (Quarterly) stood at -$2.5 million in 2021, then skyrocketed by 62.53% to -$920,749 in 2022, then surged by 131.54% to $290,430 in 2023, then skyrocketed by 110.38% to $611,000 in 2024, then skyrocketed by 96.46% to -$62,000 in 2025.
  • Its last three reported values are -$62,000 in Q3 2025, $8,000 for Q2 2025, and -$940,000 during Q1 2025.